Patent: 10,137,196
✉ Email this page to a colleague
Summary for Patent: 10,137,196
Title: | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
Abstract: | The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer. |
Inventor(s): | Govindan; Serengulam V. (Summit, NJ), Goldenberg; David M. (Mendham, NJ) |
Assignee: | Immunomedics, Inc. (Morris Plains, NJ) |
Application Number: | 15/069,208 |
Patent Claims: | see list of patent claims |
Details for Patent 10,137,196
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2032-12-13 |
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2032-12-13 |
Gilead Sciences, Inc. | TRODELVY | sacituzumab govitecan-hziy | For Injection | 761115 | 04/22/2020 | ⤷ Try a Trial | 2032-12-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |